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Abstract Physiological effects of estrogen on myocardium are
mediated by two intracellular estrogen receptors, ERK and ERL,
that regulate transcription of target genes through binding to
specific DNA target sequences. To define the role of ERL in the
transcriptional activation of both endothelial (eNOS) and
inducible nitric oxide synthase (iNOS) in cardiac myocytes, we
used the complete ERL-specific antagonist R,R-tetrahydrochry-
sene (R,R-THC). R,R-THC inhibited activation of iNOS/eNOS
promoter-luciferase reporter constructs (iNOS/eNOS-Luc) in a
dose-dependent fashion in COS7 cells selectively transfected with
ERL, but failed to influence ERK-mediated increase of iNOS/
eNOS-Luc. In neonatal rat cardiomyocytes transfected with
eNOS-Luc or iNOS-Luc, incubation with 17L-estradiol (E2,
1038 M) for 24 h stimulated expression of eNOS and iNOS.
R,R-THC (1035 M) completely inhibited this effect. Further-
more, eNOS and iNOS protein expression in cardiac myocytes
induced by E2 was completely blocked by R,R-THC as shown by
immunoblot analysis. Taken together, these results show that
ERL mediates transcriptional activation of eNOS and iNOS by
E2. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Numerous studies underline the importance of estrogenic
hormones in gender-based di¡erences found in the pathogen-
esis of cardiac diseases [1^4]. The regulatory mechanisms of
estrogen e¡ects on the myocardium, however, are still poorly
understood. Recent studies suggest that nitric oxide (NO)
plays an important role in estrogen-mediated e¡ects on myo-
cardium. NO is generated by a family of NO synthases (NOS)
which catalyze the conversion of the amino acid L-arginine to
citrulline [5]. Estrogen has been shown to increase expression
and activity of NOS in the myocardium [6,7], and this may
represent a possible mechanism for the protective role of es-
trogens on the heart. E¡ects of estrogen are mediated by
estrogen receptors (ERs) that act as ligand-activated tran-
scription factors [8,9]. Two di¡erent ERs, ERK and ERL,
have been described so far [10,11] and we have shown that
both of these receptors are expressed and functional in neo-
natal and adult cardiac myocytes [7,12]. ERL seems to be the
predominant receptor in the myocardium and thus might be
an important transducer of estrogen action. Responsiveness of
ERL expression to 17L-estradiol (E2) in cardiomyocytes is
markedly higher compared to ERK [7]. E2 action on myocar-
dium has been shown to induce non-genomic e¡ects [13,14]
and to activate a number of target genes via ER [7,12]. The
functional distinctions between ERK and ERL in this process
are not known. However, some di¡erences in signaling mech-
anisms of the ERs have already been revealed. The ability of
ER to enhance transcription of target genes has been attrib-
uted to binding to classical estrogen response elements (ERE)
and to utilizing transactivation functions (AF-1 and AF-2) to
recruit coactivator proteins of representatives of the SRC/
p160 coactivation protein family [15,16]. AF-1 and AF-2 do-
mains regulate transcription independently and synergistically,
depending on the promoter and cellular context [17,18]. Dif-
ferent regulatory functions of ERK and ERL may be in part
due to di¡erent AF-1 domains. Studies using receptor chime-
ras where the A/B region of the ERs, which contain the AF-1
domain, were interchanged have demonstrated that di¡erences
in transcriptional potency as well as response to anti-estrogens
rely on the nature of this domain [19,20]. Furthermore, ERK
and ERL have di¡erent e¡ects on cellular AP-1 activity [21,22]
and nuclear factor UB activity [23], in some cases producing
opposite e¡ects even within the same cell line. Due to the
already published di¡erences between ERK and ERL and be-
cause of the described predominant ERL responsiveness to E2
in cardiomyocytes, a detailed analysis of the functional dis-
tinctions between ERK and ERL is necessary for a complete
understanding of estrogen action in the myocardium.
A separate investigation of the roles of ERK and ERL in
the myocardium has become much easier due to the recent
development of novel, non-steroidal ligands that show sub-
type-selective di¡erences in ligand binding and transcriptional
potency for the two ERs. Speci¢cally, it has been shown that
the R,R-enantiomer of tetrahydrochrysene, R,R-THC, acts as
a complete and selective antagonist on ERL [24]. The mode of
action of R,R-THC to reveal antagonistic properties is in part
explained by its quantitative di¡erences in recruitment of co-
activator proteins such as SRC-1, -2, -3. This implies that
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while generally similar to estradiol, this ligand induces ER
conformations that di¡er somewhat from that induced by
estradiol [24].
In an e¡ort to further characterize the speci¢c role of ERL
in cardiac disease, we used R,R-THC as a pharmacological
probe to investigate the in£uence of ERL on the expression of
the inducible and endothelial NOS (iNOS, eNOS) isoforms in
neonatal rat cardiac myocytes. Dissecting the distinctive role
of the ER subtypes in the selected target tissues such as the
cardiovascular system has important implications in the use of
receptor-speci¢c antagonists and agonists in clinical medicine.
These clinical implications have been recently underlined in
the observation by Weihua et al. [47], which showed the im-
portance of ERL regulation in other sex hormone-responsive
tissues such as the prostate. In this report, we show that ERL
is a prerequisite for E2-induced increase of eNOS and iNOS
expression on the transcriptional and translational level in
cardiac myocytes.
2. Materials and methods
2.1. Materials
All chemicals were obtained from Merck (Darmstadt, Germany) if
not otherwise speci¢ed.
2.2. Cell culture
COS7 were used to selectively express transfected ERs as this cell
line expresses neither ERK nor ERL. COS7 were obtained from Amer-
ican Type Culture Collection (Manassas, VA). COS7 cells were main-
tained in Dulbecco’s modi¢ed Eagle’s medium (DMEM; Life Tech-
nologies, Karlsruhe, Germany) supplemented with 10% charcoal-
stripped, estrogen-free fetal calf serum (FCS; c.c.pro, Hamburg, Ger-
many). All media contained 25 Wg/ml gentamicin (Life Technologies).
Phenol red-free medium was used throughout all experiments as phe-
nol red is known to act as a weak estrogen [25].
2.3. Isolation and culture of neonatal cardiomyocytes
Procedures with experimental animals followed the guidelines of the
German animal protection law. The hearts of 1^2-day-old male and
female rats (Wistar^Kyoto strain) were isolated and digested with
10 ml of Spinner solution (116 mM NaCl, 5.3 mM KCl, 8 mM
NaH2PO4, 22.6 mM NaHCO3, 10 mM HEPES, 5 mM D-glucose,
pH 7.4) containing 0.1% collagenase (Cytogen, Berlin, Germany) for
10 min at 37‡C in eight consecutive steps as previously described [13].
Cell suspension was centrifuged at 400Ug for 5 min and the cell pellet
was resuspended in 20 ml of Ham’s F10 supplemented with 10% horse
serum (Biochrom, Berlin, Germany) and 10% estrogen-free FCS
(c.c.pro, Neustadt, Germany) and plated on culture dishes. After 75
min the medium which contained the cardiomyocyte fraction of the
digested tissue was removed. Cardiomyocytes were counted in a
Fuchs^Rosenthal chamber and seeded at a density of V2U104
cells/cm2 in phenol red-free DMEM supplemented with 10% char-
coal-stripped, estrogen-free FCS.
2.4. Treatment of COS7 and cardiomyocytes
Serum-starved cells were treated with E2 (1037^10310 M) þ R,R-
THC (1035^1037 M) for 24 h. Control cells were incubated with
0.1% (v/v) ethanol, the solvent of E2. Additional controls were coin-
cubated with 1038 M ICI 182.780 (Tocris, Bristol, UK), a speci¢c
inhibitor for the two known ERs [26].
After stimulation cells were rinsed with phosphate-bu¡ered saline
and lysed with 500 Wl lysate bu¡er (50 mM NaCl, 50 mM NaF, 20
mM Tris, 10 mM EDTA, 20 mM Na4P2O7, 1 mM Na3VO4, 1%
Triton X-100, 1 mM phenylmethylsulfonyl £uoride, 10 Wg/ml anti-
pain, 10 Wg/ml leupeptin, 10 Wg/ml aprotinin). Lysates were clari¢ed
by centrifugation at 12 000Ug for 10 min at 4‡C. Protein content was
measured with a standard Bradford assay.
2.5. Western blot analysis
Total cell lysates (40 Wg/lane) of each sample were subjected to
SDS^PAGE on 7.5% gels for resolution of eNOS and iNOS. Protein
was transferred electrophoretically to nitrocellulose membranes. Equal
transfer among lanes was veri¢ed by reversible staining with Ponceau
red. Immunoblotting was performed with antibodies speci¢c for
eNOS (rabbit polyclonal, 1:1000, #482726, Calbiochem, Bad Soden,
Germany) and iNOS (rabbit polyclonal, 1:2000, #482728, Calbio-
chem). Detection was performed with the Enhanced Chemilumines-
cence technique (NEN Life Science, Cologne, Germany). Densitomet-
ric analysis of immunoblots was performed with the Gel Doc 1000
imaging system using the analysis software Multi-Analyst (Bio-Rad
Laboratories, Munich, Germany).
2.6. Transient transfections
COS7 cells and neonatal cardiomyocytes were grown to an approx-
imate density of 70% and transfected using a liposome-conjugated
transfection technique according to the manufacturer’s instructions
(DOTAP; Roche Diagnostics, Mannheim, Germany). COS7 cells
were transiently transfected with the respective ER expression vectors
(human ERK, HEG0, kind gift from Dr. P. Chambon and rat ERL,
pCMV29, kind gift from Dr. G. Kuiper) and the reporter plasmids
ERE-Luc that contain three copies of an estrogen-responsive element
from the Xenopus vitellogenin gene linked to a luciferase gene under
control of a thymine kinase promoter (kindly provided by Dr. C.
Glass). Additionally cells were cotransfected with an eNOS promoter
construct containing 1.6 kb upstream of the human eNOS gene
(eNOS-Luc, kindly provided by Dr. C.J. Lowenstein) [27] or an
iNOS promoter containing 1122 kb upstream of human iNOS gene
(iNOS-Luc, kindly provided by Dr. N.E. Madias) cloned upstream of
a luciferase reporter gene in a pGL2-Basic plasmid [28]. 2 Wg total
DNA per assay was found to give maximal e⁄ciency. As an internal
control of transfection e⁄ciency 2 ng of L-galactosidase expression
plasmid pL7RH-Gal was cotransfected. After transfection cells were
washed, medium was changed to serum-free with addition of
E2 þ R,R-THC as described in Section 2.4. Cells were lysed 48 h after
transfection and assayed for luciferase and L-galactosidase activity as
described previously [29].
3. Results
Although it has been shown before that E2 stimulates the
expression of eNOS and iNOS in cardiac myocytes [7], the
speci¢c roles of ERK and ERL in this process are not known.
In order to de¢ne the in£uence of both ERs on the transcrip-
tional regulation of NOS we used the ER subtype-selective
ligand R,R-THC.
As an initial step we examined the transactivation proper-
ties of ERK and ERL at a classical ERE in response to R,R-
THC. COS7 cells which are devoid of ERs were cotransfected
with expression plasmids for ERK or ERL together with a
reporter plasmid that contained an ERE linked to luciferase
(ERE-Luc). These cells were treated with increasing concen-
trations of R,R-THC, or with E2 for comparison. Maximal
transactivation of ERE-Luc in ERL- and in ERK-transfected
cells was seen at a dose of 1038 M E2. R,R-THC did not show
any agonistic activity in the presence of ERK in COS7 cells
and did not in£uence E2-mediated transactivation by ERK
(Fig. 1A). Although agonistic properties of R,R-THC on
ERK have been shown in HEC-1 and CHO cells [24,30], in
COS7 cells we could not observe any agonistic activity on
ERK. These di¡erences in agonistic properties of R,R-THC
may depend greatly on the cellular background and promoter
context and/or on di¡erent protocols used in cell and ligand
treatment. In ERL-transfected cells R,R-THC clearly exhib-
ited antagonistic activity in a dose-dependent manner and
completely inhibited E2-mediated transcriptional activation
by ERL at a dose of 1035 M (Fig. 1B).
To control whether R,R-THC is also capable of in£uencing
the E2-dependent iNOS and eNOS transactivation, COS7
cells were selectively transfected with expression plasmids for
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ERK or ERL and for iNOS-Luc or eNOS-Luc promoters as
reporter constructs. These cells were incubated with E2 or
vehicle alone for 24 h (Fig. 2). E2 (1038 M) stimulated the
expression of iNOS-Luc (maximum: 8.38 þ 0.02-fold com-
pared to vehicle-treated control) and eNOS-Luc (maximum:
7.87 þ 0.02-fold compared to vehicle-treated control) in the
presence of ERK as well as in presence of ERL. Coincubation
with R,R-THC inhibited activation of iNOS-Luc and eNOS-
Luc expression in a dose-dependent fashion in cells selectively
transfected with ERL, but failed to in£uence ERK-mediated
increase of iNOS/eNOS-Luc. Complete inhibition of both
eNOS-Luc and iNOS-Luc expression in ERL-transfected cells
was obtained at a dose of 1035 M. In cells which were co-
treated with ICI 182.780 (1038 M), a speci¢c inhibitor of the
two known ERs, activation of the reporter constructs was also
prevented. Neither R,R-THC nor ICI 182.780 could transac-
tivate the promoter constructs. In the absence of ERK or ERL
activation of iNOS-Luc and eNOS-Luc was low and could
not be increased by E2 (data not shown).
After the demonstration that R,R-THC acts as a complete
ERL antagonist and selectively inhibits ERL-mediated trans-
activation of iNOS-Luc and eNOS-Luc in a dose-dependent
fashion, we used neonatal cardiomyocytes to describe the role
of ERL in the heart.
Neonatal rat cardiac myocytes which are known to express
both ERK and ERL were transfected with iNOS-Luc and
eNOS-Luc and incubated with E2 (1038 M) for 24 h. E2
stimulated the expression of eNOS-Luc (maximum: 9.46 þ
0.09-fold) (Fig. 3A) and iNOS-Luc (maximum: 9.41 þ 0.06-
fold) expression (Fig. 3B). Coincubation with R,R-THC
(1035^1037 M) inhibited the transactivation of both promoter
constructs in a dose-dependent fashion suggesting a speci¢c
role for ERL in E2-mediated activation of NOS. Treatment
with R,R-THC alone had no e¡ect on eNOS and iNOS pro-
moter constructs. Control experiments using ICI 182.780
(1038 M) demonstrated a complete inhibition of E2-mediated
activation of both reporter constructs in cardiac myocytes.
Fig. 1. Transcriptional activation of ERE-Luc by ERK (A) and
ERL (B) in response to E2 and R,R-THC in COS7 cells. ER-nega-
tive COS7 cells were cotransfected with either ERK or ERL expres-
sion vectors together with an estrogen-responsive reporter gene
(ERE-Luc) and treated with E2 and R,R-THC for 24 h in increas-
ing concentrations. Additionally cells were cotreated with E2 (1038
M) and increasing concentrations of R,R-THC (1038^1035 M). Luc
activity was determined and plotted as fold activation over the indi-
vidual Luc activity measured in cells treated with vehicle alone. Val-
ues represent the mean þ S.E.M. for at least three independent trans-
fections performed in triplicate.
Fig. 2. Transcriptional activation of eNOS and iNOS promoter-lu-
ciferase reporter constructs by ERK and ERL in response to E2 and
R,R-THC in COS7 cells. ER-negative COS7 cells were cotransfected
with either ERK or ERL expression vectors together with an eNOS
or iNOS promoter reporter gene (A: eNOS-Luc, B: iNOS-Luc) and
treated with E2 (1038 M) and R,R-THC for 24 h in increasing con-
centrations (1035^1037 M). Additional cells were cotreated with the
complete ER antagonist ICI 182.780 (ICI, 1038 M). Luc activity
was determined and plotted as fold activation over the individual
Luc activity measured in cells treated with vehicle alone. Values rep-
resent the mean þ S.E.M. for at least three independent transfections
performed in triplicate.
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To determine if ERL-mediated e¡ects on the iNOS and
eNOS promoter were present also on the protein level an
immunoblot analysis was performed. We therefore analyzed
the expression pattern of eNOS and iNOS in the absence and
presence of E2 and R,R-THC in cardiac myocytes. Immuno-
blot analyses of lysates from cardiomyocytes identi¢ed a band
with a molecular weight of 140 kDa, corresponding to the
expected size of eNOS (Fig. 4A) and iNOS (130 kDa; Fig.
4B). In the absence of estrogen a signal was detected, but
incubation with physiological concentrations of E2 (1038 M)
for 24 h led to a marked increase in the abundance of the
respective proteins (iNOS: 2.3 þ 0.59-fold after 24 h; eNOS:
2.15 þ 0.24-fold after 24 h). Cotreatment with R,R-THC in-
hibited activation of protein expression of eNOS as well as
iNOS. Coincubation with the speci¢c pure estrogen antagonist
ICI 182.780 also inhibited the upregulation of both NOS pro-
teins by E2. Treatment with R,R-THC and ICI 182.780 alone
did not a¡ect the expression of eNOS and iNOS.
4. Discussion
The ability of the two estrogen receptor subtypes to display
distinct or even opposing transcriptional activities is an
emerging paradigm in estrogen signaling. Although ERK
and ERL share a high degree of amino acid homology there
are major di¡erences between these receptors for instance with
respect to their tissue distribution, their ligand binding specif-
icity and also with respect to the phenotype of the corre-
sponding knock-out mice [31^33]. Both receptors are ex-
Fig. 3. Transcriptional activation of eNOS and iNOS promoter-lu-
ciferase reporter constructs in response to E2 is inhibited by R,R-
THC in neonatal rat cardiac myocytes. Neonatal cardiac myocytes
which contain both ER subtypes were transfected with an eNOS or
iNOS promoter reporter gene (A: eNOS-Luc, B: iNOS-Luc) and
treated with E2 (1038 M) alone and together with R,R-THC for 24
h in increasing concentrations (E2: 1038 M, THC: 1035^1037 M).
Additional cells were cotreated with the complete ER antagonist
ICI 182.780 (ICI, 1038 M). Luc activity was determined and plotted
as fold activation over the individual Luc activity measured in cells
treated with vehicle alone. Values represent the mean þ S.E.M. for
at least three independent transfections performed in triplicate.
Fig. 4. R,R-THC inhibits E2-stimulated eNOS and iNOS expression
in neonatal rat cardiac myocytes. Neonatal rat cardiac myocytes
were cultured in serum-free de¢ned medium in the absence or pres-
ence of E2 (1038 M). Cell lysates of cardiomyocytes (40 Wg protein/
lane) were subjected to SDS^PAGE and immunoblotted with specif-
ic primary antibodies directed against the eNOS protein (A) and
iNOS protein (B). In representative immunoblots shown in A and
B, the protein was detectable at the expected size of 130 kDa
(iNOS, panel A) and 140 kDa (eNOS, panel B). Note that the level
of expression of both NOS proteins is low in the absence of E2
(Control, 1) but increases markedly in cells exposed to E2 (1039 M)
for 24 h (2). Coincubation with R,R-THC (1035 M) completely in-
hibited E2-induced expression of eNOS and iNOS (3). Cotreatment
with ICI 182.780 (1038 M) for 24 h also inhibited the estrogen-
mediated increase in NOS expression (4). R,R-THC (5) and ICI
182.780 (6) alone had no e¡ect on protein expression. Summary
¢ndings are shown in the compiled bar graphs representing the ex-
pression of iNOS and eNOS relative to the untreated controls. Ex-
pression was determined by densitometric analysis of immunoblots
and results are mean þ S.E.M. from three independent experiments.
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pressed and functional in cardiac tissue [12,13], supporting a
direct role for estrogen in cardiac physiology.
In the present work we show for the ¢rst time di¡erent
transactivation properties between the two receptors in a cel-
lular background which contains both receptors. We were
able to demonstrate that NOS, as important physiological
estrogen target genes in the heart, are regulated via ERL. In
particular, our data show that endogenous ERL is necessary
to mediate an upregulation of iNOS and eNOS in neonatal
rat cardiac myocytes. The promoters of iNOS and eNOS have
been cloned and analyzed in detail. This analysis revealed the
existence of several half-palindromic ER binding sequences on
the promoter [34,35], which make it plausible that estrogen
can transcriptionally regulate NOS genes, leading to enhanced
NO production. NO has been claimed to in£uence a variety of
physiological parameters in the heart such as contraction,
relaxation and heart rate [36^39].
Up to now the investigation of how ERK and ERL contrib-
ute to the transcriptional activation of eNOS and iNOS has
been hampered by the lack of speci¢c ERL antagonists. There-
fore, the recent development the a new non-steroidal ligand
R,R-THC, which acts as an ERL-speci¢c antagonist, allows us
to further dissect the respective roles of the ERs in this pro-
cess.
The molecular basis underlying the reported di¡erent tran-
scriptional properties between the ERs is poorly understood
at the present time. ERL displays extensive sequence similarity
to ERK, however there are signi¢cant di¡erences in the C-
terminal ligand binding domain and in the N-terminal trans-
activation domain [11]. These structural di¡erences probably
account for di¡erential binding of several estrogenic chemicals
and several phytoestrogens to ERK and ERL protein [40] and
may also account for di¡erent transcriptional activity. Tran-
scriptional activation is strongly in£uenced by cell and pro-
moter context [19]. Therefore it is to be expected that the two
receptors might have distinct functions and interact with dif-
ferent sets of proteins such as SRC/p160 or MAD2, which has
been identi¢ed as a protein that interacts speci¢cally with ERL
but not with ERK [41]. Furthermore, ERL has been identi¢ed
to play an important role in the control of growth by an
interaction with other nuclear receptors [47], which demon-
strates the need to investigate the tissue-speci¢c properties
of ER subtypes in a hormone-sensitive cellular context which
expresses both receptors endogenously.
In our experiments, inhibition of ERL by R,R-THC pre-
vented upregulation of eNOS and iNOS expression. What
does that mean in the context of ER signaling? The antago-
nistic action of R,R-THC on ERL will prevent activated ho-
modimers of ERL and will prevent an activated ERL compo-
nent in heterodimers. As R,R-THC blocked the upregulation
of iNOS and eNOS expression in cardiac myocytes, ERK
homodimers do not seem to be able to induce this expression.
Thus heterodimers containing activated ERL or ERL homo-
dimers seem to be necessary in cardiomyocytes to activate E2-
induced NOS expression. Coexpression of ERK and ERL re-
sults in the preferential formation of heterodimers instead of
homodimers [42,43]. It has been shown that transcriptional
activation could occur if only one of the ER subtypes within
the heterodimer was bound by E2 [44]. Colocalization and
subsequent heterodimerization in cardiomyocytes may there-
fore result in receptor activity distinct from that of homo-
dimers. In accordance with our observations, alterations in
transcriptional activity resulting from coexpression of ERK
and ERL have been described recently, and ERL has been
found to act as a dominant regulator of estrogen signaling
[45,46].
The use of R,R-THC has been shown to be instrumental in
the dissection of the role of ER subtypes in tissues which
express both receptor subtypes endogenously. In this context
it is important to note that the ERL bound with R,R-THC
fails to recruit p160 coactivator proteins [30]. The recruitment
of di¡erent coactivator proteins in selective target tissues adds
a new dimension in the regulatory network involved in re-
sponse to estrogen. The extent of conformational changes
induced by the di¡erent use of di¡erent ligands and the ability
to recruit di¡erent coactivator proteins of ER subtypes plays
an increasing role in the regulatory network of hormone ac-
tion. The e¡ort to understand the complexity of estrogenic
action on the myocardium is substantiated by the use of these
novel ligand compounds with their ability to promote trans-
activation and coactivator recruitment. The understanding of
these mechanisms is critical and these observations will ulti-
mately lead to the use of receptor-speci¢c selective estrogen
receptor modulators in clinical medicine.
In conclusion, we demonstrated that in cardiac myocytes
ERL is essential to regulate the activity of NOS. However,
the particular roles of ERK and ERL homo- and heterodimer-
ization and their distinct pattern in coactivator recruitment,
which ultimately leads to NOS activation in the myocardium,
remain to be further investigated. We suggest that coexpres-
sion of both receptors may lead to a regulatory mechanism
with antagonist and agonist features. This principle may well
play an important role in the cellular response to physiolog-
ical and pathophysiological responses such as oxidative stress
or ischemia in the myocardium. These ¢ndings may help to
elucidate the distinct roles of ERK and ERL in the patho-
genesis of gender-based di¡erences found in cardiac disease.
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